Jim Cramer Says Buy Celgene (CELG) on Weakness Over Revlemed - Presented by: The Aol. On Network

TheStreet's Jim Cramer says Celgene (CELG), which ended Friday's session down more than 4-percent, is a great buy because the drugmaker is led by a great CEO. Cramer says Celgene CEO Robert Hugin has done a great job of diversifying the company's drug portfolio. Shares of Celgene ended lower on word the UK would not immediately approve Celgene's cancer drug, Revlemed, for reimbursement. Cramer believes the drug will eventually be approved for reimbursement everywhere.



Related Videos

Most Popular Videos

Latest Videos


Most Active by Volume

Company Last Sale Change Net / %
RAD $ 6.69 0.36 ▼ 5.11%
SIRI $ 3.38 0.06 ▼ 1.74%
AAPL $ 99.02 1.35 ▲ 1.38%
FB $ 74.92 0.27 ▼ 0.36%
BAC $ 15.50 0.09 ▼ 0.58%
MU $ 31.98 1.44 ▼ 4.31%
GE $ 25.59 0.20 ▼ 0.78%
DLTR $ 54.87 0.65 ▲ 1.20%

As of 7/28/2014, 04:05 PM
More Most Active